#USA #Los Angeles #Schall Law Firm #Securities Fraud #Unicycive

Unicycive Therapeutics Faces Class Action Lawsuit

In a recent development, investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) are reminded of a class action lawsuit spearheaded by The Schall Law Firm, a reputable name in shareholder rights litigation. The firm highlights significant allegations against Unicycive concerning violations of the Securities Exchange Act of 1934.

Background of the Case

The legal action focuses on the claims that Unicycive made false and misleading statements concerning its compliance with the FDA regulations related to drug manufacturing. During the class period, spanning from March 29, 2024, to June 27, 2025, investors who purchased Unicycive securities might have incurred substantial losses due to these alleged misrepresentations.

The firm is urging affected investors to contact them before October 14, 2025, to discuss their potential involvement in the lawsuit. As noted by Brian Schall, a principal of the firm, this is a critical opportunity for investors to secure their rights without any upfront costs.

Allegations Against Unicycive

According to the lawsuit, Unicycive overstated its ability to meet the FDA's stringent manufacturing compliance standards. Furthermore, it allegedly exaggerated the prospects of obtaining FDA approval for its drug, OLC, which is intended to treat hyperphosphatemia in patients with chronic kidney disease undergoing dialysis. These statements led investors to believe in the security and potential returns of their investments, only for the reality to reveal that the company's claims were unfounded and materially misleading.

As the truth about Unicycive began to emerge, a significant impact on the company's stock price was observed, leading to investor losses.

Understanding Your Rights

For investors who feel affected, joining this class action is essential. The Schall Law Firm specializes in representing investors globally and focuses on securities class action lawsuits. By participating, affected investors have the opportunity to recover some of their losses as the legal powers of an organized class come into play.

When contemplating involvement in this lawsuit, it is important for investors to understand that the class certification has not yet occurred. Until the certification is granted, an investor may be regarded as an absent class member, which limits their ability to recover any losses.

How to Get Involved

Investors may reach out to The Schall Law Firm directly via multiple channels. Those interested can contact the firm at: 2049 Century Park East, Suite 2460, Los Angeles, CA 90067. Phone inquiries can be directed to 310-301-3335. For further details, their official website at www.schallfirm.com provides comprehensive information, and interested parties may email the firm at [email protected].

In conclusion, the ongoing situation with Unicycive Therapeutics presents an important reminder to investors about the importance of due diligence and the implications of potential securities fraud within the market. As this case unfolds, the Schall Law Firm represents a critical resource for shareholders seeking justice and accountability.

Investors are encouraged to assess their circumstances by the approaching deadline to ensure their voices are heard in this significant legal matter.